Xilio Therapeutics (XLO) Return on Assets (2021 - 2026)

Xilio Therapeutics (XLO) has 6 years of Return on Assets data on file, last reported at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Assets changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.01%, up 1.0% from the prior year.
• Return on Assets grew to 0.0% in Q1 2026, from 0.0% in the prior quarter.
• In the past five years, Return on Assets ranged from a high of 0.0% in Q1 2026 to a low of 0.01% in Q4 2023.
• A 5-year average of 0.01% and a median of 0.01% in 2025 frame the typical range for Return on Assets.
• Across the five-year window, Return on Assets fell 1 bps in 2023 and grew 1 bps in 2025, its largest moves.
• Tracing XLO's Return on Assets over 5 years: stood at 0.01% in 2022, then slumped by 89 bps to 0.01% in 2023, then increased by 27 bps to 0.01% in 2024, then soared by 65 bps to 0.0% in 2025, then increased by 9 bps to 0.0% in 2026.
• Business Quant data shows XLO's Return on Assets at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.